Workflow
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
BEAMBeam Therapeutics(BEAM) Zacks Investment Research·2024-05-08 15:56

Beam Therapeutics Inc. (BEAM) incurred a loss of 1.21pershareinthefirstquarterof2024,narrowerthantheZacksConsensusEstimateofalossof1.21 per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 1.45. The company had recorded a loss of 1.33pershareintheyear−agoquarter.Totalrevenues,comprisinglicenseandcollaborationrevenues,cameinat1.33 per share in the year-ago quarter.Total revenues, comprising license and collaboration revenues, came in at 7.4 million in the first quarter compared with 24.2millionintheyear−agoperiod.ThetoplinemissedtheZacksConsensusEstimateof24.2 million in the year-ago period. The top line missed the Zacks Consensus Estimate of 14 million.Quarter in DetailResearch and development expenses amou ...